Analyst Report: MRNA
1. EXECUTIVE SUMMARY
Moderna closed at $236.50 on Thursday 15 October 2026, up 20.05% from $197.00 on 8 October, and set a 52-week high of $242.29 intraday on the final session. Most of the weekly gain arrived on 9 October, when the stock rose 14.21% after a New York Times report that the NIH is preparing a public-private cancer vaccine initiative and after Moderna joined the Nasdaq-100 (Yahoo Finance and Investing.com, 9 October). Three further sessions added gains of between 1% and 5% each, with a Goldman Sachs target increase on 15 October as the only dated catalyst in the brief. The NIH report names no contract or funding for Moderna, so the rally rests largely on anticipation of the full Phase 3 melanoma data on 24 October. Goldman says a recurrence-free survival hazard ratio below 0.70 is needed to support the current share price.
2. THE CATALYST
The brief describes the week in stages.
| Session | Close | Change | Driver per brief |
|---|---|---|---|
| 8 Oct | $197.00 | +0.26% | No story found; volume of 37,400,000 ran ahead of the 9 October report |
| 9 Oct | $225.00 | +14.21% | NIH cancer vaccine report and Nasdaq-100 inclusion |
| 12 Oct | $213.74 | -5.00% | Profit-taking with analysts pointing to valuation (TradingKey) |
| 13 Oct | $216.25 | +1.17% | No cause in the brief |
| 14 Oct | $226.30 | +4.65% | No matching story found |
| 15 Oct | $236.50 | +4.51% | Goldman Sachs target raised; fresh 52-week high |
The Wall Street Journal, as relayed by Qz on 12 October, attributed the 9 October gains to the New York Times report and to Moderna replacing Warner Bros. in the Nasdaq-100. Nasdaq announced the inclusion on 1 October (Ad-hoc News, 12 October). JournalArta (10 October) reported that the sources identified no specific contract, funding award or role for Moderna in the NIH plan. Motley Fool (9 October) listed pancreatic, liver and colorectal cancer and pediatric tumors as initial focus areas.
On 15 October, Goldman Sachs analyst Salveen Richter raised the price target from $120 to $137 and kept a Neutral rating (MarketBeat and GuruFocus, 15 October). Stocktwits reported the stock hit a fresh 52-week high that session on the note. The brief does not establish the intraday timing of the note.
Details of the NIH program conflict across sources: BNEWSO (2 October) describes a $250m "OncoVax Accelerate" program, while TIKR (13 October) describes a $200m Therapeutic Cancer Vaccines Initiative through the Foundation for the NIH. Neither figure is verified.
3. COMPANY PROFILE
Moderna is a Healthcare and Biotechnology company with a $94.42bn market cap. It develops messenger RNA medicines, spanning respiratory vaccines (Spikevax, mNEXSPIKE, mRESVIA, and candidates for influenza and combination shots), latent virus vaccines, norovirus, public health vaccines and an oncology line that includes intismeran autogene. Competitors named in the brief as moving with it include Pfizer, BioNTech, Merck and Novavax.
Recent results per MarketBeat (15 October): second-quarter 2026 revenue of $145m and an adjusted loss of $1.97 per share against a projected $2.03 loss. 24/7 Wall St. cites a $782m second-quarter loss. The same outlet reports that management expects about 55% of second-half revenue in the third quarter and year-end cash of $4.7bn to $5.2bn; this comes from a secondary source and needs checking against the company release.
The Phase 3 trial of intismeran autogene with Keytruda met its primary endpoint of recurrence-free survival, announced in August (Stocktwits). Per 24/7 Wall St., the shares rose 177% on 19 August, the best day on record. The companies plan to seek approval next year (Yahoo Finance via WSJ, 9 October).
4. DEEP DIVE ANALYSIS
Fundamentals. The facts show a forward P/E of -53.3, so the $94.42bn valuation rests on pipeline expectations. The stock is up 666.36% year to date and 307.27% over 60 sessions. The NIH report offers Moderna no stated financial benefit, so the 9 October rise reflects sentiment and index demand. Inference: Nasdaq-100 inclusion added forced buying from index-tracking funds around that session, which would partly explain the 37,400,000 shares traded on 8 October.
Sector read-across. Peers in biotechnology rose between 1.09% (VRTX) and 7.75% (BIIB) over the same period, with REGN +7.68%, GILD +6.98%, AMGN +6.53% and ABBV +4.67%. Moderna's 20.05% gain is well ahead of all of them. JournalArta reported that Novavax rose 15% on 9 October with gains in Pfizer, BioNTech and Merck. The S&P 500 fell 0.27% over the period.
Comparable episodes. After the 177% jump on 19 August, Moderna fell about 20% the next day (24/7 Wall St.). A 5.00% retreat followed the 9 October rally. On 30 September, a Citigroup downgrade to Sell, citing valuation, pushed the stock down nearly 6% in premarket trading (StockAnalysis).
Analyst positioning. Every target in the brief sits below the $236.50 close.
| Firm | Rating | Target | Date |
|---|---|---|---|
| Goldman Sachs | Neutral | $137 (from $120) | 15 Oct |
| Bank of America | Neutral | $200 (from $170) | 9 Oct |
| Citigroup | Sell | $80 (from $60) | 30 Sep |
MarketBeat shows a consensus target of $101.45 with a Hold rating, and Koyfin's 12-month average is $122.67 (Stocktwits and 24/7 Wall St., 15 October). Rating counts differ by source: MarketBeat has 7 Buy, 15 Hold and 4 Sell, while Koyfin reports 5 of 23 at Buy or higher.
Bull case. The August readout met its primary endpoint, full data arrive on 24 October, and approval filings are planned for next year. A hazard ratio below 0.70 would meet Goldman's threshold. The NIH initiative, expected to launch in December (Motley Fool), could widen the market for cancer vaccines.
Bear case. The price sits well above every analyst target in the brief. The NIH news carries no direct benefit, the company posts losses, and the 19 August episode saw a sharp reversal after a news spike. Citigroup cited valuation in its downgrade.
5. TECHNICAL SNAPSHOT
The close of $236.50 is the highest in the daily table and sits just below the 52-week high of $242.29 set intraday on 15 October, so no resistance level is available from the table. It is well above the 50-day average of $151.65 and the 200-day average of $76.46, and far above the 52-week low of $22.28. The nearest support is $226.30, the 14 October close. Last-session volume of 17,290,300 was 0.77x the 50-day average of 22,504,874, which means the latest highs came on lighter trading than usual. The heaviest volumes of the table came on 8 and 9 October.
6. RISK FACTORS
- Melanoma data, 24 October: the full Phase 3 results at ESMO with Merck, with a Moderna investor call the same day (Ad-hoc News; Stocktwits). A hazard ratio at or above Goldman's 0.70 threshold would pressure the price.
- Sell-the-news pattern: the 19 August precedent saw a roughly 20% fall the day after a major jump.
- Valuation: the stock trades far above published targets, and Citigroup's downgrade cited valuation.
- Q3 results, 6 November: consensus EPS is -1.3 and revenue $892.38m (facts).
- NIH program: details are unverified and conflict between sources, with a December launch expected.
- Pancreatic cancer data: early safety and immune-response results are upcoming per Goldman's note, with no date given.
- Unconfirmed items: headlines about sector rotation into healthcare on 15 October could not be opened, and the brief treats them as unconfirmed.
7. ACTIONABLE OUTLOOK
Short term (1-2 weeks). The 24 October data dominate. Inference: positioning ahead of the readout explains the climb on 14 and 15 October, for which the brief finds no other story. The stock has gone from $197.00 to $236.50 in a week, and the August precedent shows moves of that size can reverse quickly once results are public. Support is at $226.30, and the intraday high of $242.29 is the level to clear.
Medium term (1-3 months). Results on 6 November and the December NIH launch follow the data. A hazard ratio below 0.70 would meet Goldman's stated bar, while a weaker figure would leave a stock trading well above every target in the brief without its main support. Analyst targets will probably be revised after the readout.
Long term. The brief shows no change to the thesis: the melanoma program met its primary endpoint in August, and approval filings are planned for next year. The open question is how much of that outcome the $94.42bn market cap already includes.
This is analysis only and not personal financial advice.